Concurrent or sequential adjuvant letrozole and radiotherapy after conservative surgery for early-stage breast cancer (CO-HO-RT): a phase 2 randomised trial.

Détails

ID Serval
serval:BIB_F0D3E362858F
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Institution
Titre
Concurrent or sequential adjuvant letrozole and radiotherapy after conservative surgery for early-stage breast cancer (CO-HO-RT): a phase 2 randomised trial.
Périodique
Lancet Oncology
Auteur⸱e⸱s
Azria David, Belkacemi Yazid, Romieu Gilles, Gourgou Sophie, Gutowski Marian, Zaman Khalil, Moscardo Carmen Llacer, Lemanski Claire, Coelho Michael, Rosenstein Barry, Fenoglietto Pascal, Crompton Nigel E. A., Ozsahin Mahmut
ISSN
1474-5488[electronic], 1470-2045[linking]
Statut éditorial
Publié
Date de publication
2010
Volume
11
Numéro
3
Pages
258-265
Langue
anglais
Résumé
BACKGROUND: Letrozole radiosensitises breast cancer cells in vitro. In clinical settings, no data exist for the combination of letrozole and radiotherapy. We assessed concurrent and sequential radiotherapy and letrozole in the adjuvant setting. METHODS: This phase 2 randomised trial was undertaken in two centres in France and one in Switzerland between Jan 12, 2005, and Feb 21, 2007. 150 postmenopausal women with early-stage breast cancer were randomly assigned after conserving surgery to either concurrent radiotherapy and letrozole (n=75) or sequential radiotherapy and letrozole (n=75). Randomisation was open label with a minimisation technique, stratified by investigational centres, chemotherapy (yes vs no), radiation boost (yes vs no), and value of radiation-induced lymphocyte apoptosis (< or = 16% vs >16%). Whole breast was irradiated to a total dose of 50 Gy in 25 fractions over 5 weeks. In the case of supraclavicular and internal mammary node irradiation, the dose was 44-50 Gy. Letrozole was administered orally once daily at a dose of 2.5 mg for 5 years (beginning 3 weeks pre-radiotherapy in the concomitant group, and 3 weeks post-radiotherapy in the sequential group). The primary endpoint was the occurrence of acute (during and within 6 weeks of radiotherapy) and late (within 2 years) radiation-induced grade 2 or worse toxic effects of the skin. Analyses were by intention to treat. This study is registered with ClinicalTrials.gov, number NCT00208273. FINDINGS: All patients were analysed apart from one in the concurrent group who withdrew consent before any treatment. During radiotherapy and within the first 12 weeks after radiotherapy, 31 patients in the concurrent group and 31 in the sequential group had any grade 2 or worse skin-related toxicity. The most common skin-related adverse event was dermatitis: four patients in the concurrent group and six in the sequential group had grade 3 acute skin dermatitis during radiotherapy. At a median follow-up of 26 months (range 3-40), two patients in each group had grade 2 or worse late effects (both radiation-induced subcutaneous fibrosis). INTERPRETATION: Letrozole can be safely delivered shortly after surgery and concomitantly with radiotherapy. Long-term follow-up is needed to investigate cardiac side-effects and cancer-specific outcomes. FUNDING: Novartis Oncology France.
Mots-clé
Growth-Factor-Beta, Radiation-Therapy, Aromatase-Activity, European-Organization, Lymphocyte Apoptosis, Adipose-Tissue, Late Toxicity, Tamoxifen, Fibrosis, System
Pubmed
Web of science
Création de la notice
29/03/2010 14:36
Dernière modification de la notice
20/08/2019 16:18
Données d'usage